HUTCHMED (China) (HCM) EBITDA: 2014-2025
Historic EBITDA for HUTCHMED (China) (HCM) over the last 4 years, with Jun 2025 value amounting to -$5.5 million.
- HUTCHMED (China)'s EBITDA rose 42.42% to -$5.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$25.4 million, marking a year-over-year increase of 90.65%. This contributed to the annual value of -$2.6 million for FY2024, which is 114.00% down from last year.
- According to the latest figures from Q2 2025, HUTCHMED (China)'s EBITDA is -$5.5 million, which was down 113.37% from -$2.6 million recorded in Q4 2024.
- In the past 5 years, HUTCHMED (China)'s EBITDA ranged from a high of $220.6 million in Q1 2021 and a low of -$252.5 million during Q4 2021.
- Moreover, its 3-year median value for EBITDA was -$6.6 million (2023), whereas its average is -$6.3 million.
- The largest annual percentage gain for HUTCHMED (China)'s EBITDA in the last 5 years was 14,767.91% (2021), contrasted with its biggest fall of 5,738.93% (2021).
- HUTCHMED (China)'s EBITDA (Quarterly) stood at -$252.5 million in 2021, then skyrocketed by 99.25% to -$1.9 million in 2022, then reached -$7.8 million in 2023, then fell by 22.23% to -$2.6 million in 2024, then spiked by 42.42% to -$5.5 million in 2025.
- Its EBITDA was -$5.5 million in Q2 2025, compared to -$2.6 million in Q4 2024 and -$9.5 million in Q2 2024.